Optimizing higher throughput methods to assess drug-drug interactions for CYP1A2, CYP2C9, CYP2C19, CYP2D6, rCYP2D6, and CYP3A4 in vitro using a single point IC50

Journal of Biomolecular Screening

Volumn 7, Issue 4, 2002, Pages 373-382

  Gao, Feng ^a   Johnson, Diane L ^a   Ekins, Sean ^b   Janiszewski, John ^a   Kelly, Kevin G ^a   Meyer, R Daniel ^a   West, Michael ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^b Concurrent Pharmaceuticals Inc ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUFURALOL; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DICLOFENAC; FURAFYLLINE; ISOCITRATE DEHYDROGENASE; KETOCONAZOLE; MEPHENYTOIN; PHENACETIN; PHENACETIN O DEETHYLASE; QUINIDINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SULFAPHENAZOLE; TICLOPIDINE; CYP2C19 PROTEIN, HUMAN; CYP2C9 PROTEIN, HUMAN; CYTOCHROME P450; ISOENZYME; MIXED FUNCTION OXIDASE; RECOMBINANT PROTEIN; UNSPECIFIC MONOOXYGENASE;

ARTICLE; CONCENTRATION RESPONSE; CORRELATION ANALYSIS; DRUG INHIBITION; ENZYME SUBSTRATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IC 50; IN VITRO STUDY; INHIBITION KINETICS; MICROSOME; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; ALGORITHM; AUTOMATION; COMPUTER SIMULATION; DRUG ANTAGONISM; DRUG INTERACTION; DRUG SCREENING; ENZYMOLOGY; LIVER; LIVER MICROSOME; METABOLISM; METHODOLOGY; STATISTICAL MODEL;

ALGORITHMS; ARYL HYDROCARBON HYDROXYLASES; AUTOMATION; COMPUTER SIMULATION; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; DRUG EVALUATION, PRECLINICAL; DRUG INTERACTIONS; INHIBITORY CONCENTRATION 50; ISOENZYMES; LIVER; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; MODELS, STATISTICAL; RECOMBINANT PROTEINS;

EID: 0036671008     PISSN: 10870571     EISSN: None     Source Type: Journal    
DOI: 10.1089/108705702320351231     Document Type: Article

References (49)

1. Systematic screening for pharmacokinetic interactions during drug development
2. Screening studies for metabolism and toxicology
3. The rational selection of drug interaction studies: Implications of recent advances in drug metabolism
4. Goals, design, timing, and future opportunities for non clinical drug metabolism studies
5. Inhibition of cytochrome P-450 and implications in drug development
6. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians
7. Human cytochrome P450s: Selectivity and measurement in vivo
8. 450 and the clinical implications
9. 450 (CYP) enzymes: Assessment of human CYP inhibition potential
10. Preclinical drug metabolism in the age of high-throughput screening: An industrial perspective
11. High-throughput approaches for evaluating absorption, distribution, metabolism and excretion properties of lead compounds
12. Screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes
13. Prediction of pharmacokinetic alterations caused by drug-drug interactions: Metabolic interaction in the liver
14. The PXR crystal structure: The end of the beginning
15. HPLC-API/MS/MS: A powerful tool for integrating drug metabolism into the drug discovery process
16. A high through put screening assay for CYP3A4 interactions using SPA
17. [O-ethyl-14C]-phenacetin O-deethylase activity in human liver microsomes
18. Microtiter plate assays for inhibition of human drug-metabolizing cytochromes P450
19. 450 metabolism
20. A microassay for measuring cytochrome P450IA1 and P450IIB1 activities in intact human and rat hepatocytes cultured on 96-well plates
21. 450 enzymes using a simple in vitro inhibition screen
22. Virtual kinetics: Using statistical experimental design for rapid analysis of enzyme inhibitor mechanisms
23. Experimental design for high-throughput screening
24. Design of signal windows in high throughput screening assays for drug discovery
25. Single point screening for high throughput methods to predict drug-drug interaction potential
26. Three dimensional-quantitative structure activity relationship (3D-QSAR) analyses of inhibitors for CYP3A4
27. Three dimensional-quantitative structure activity relationship (3D-QSAR) analyses of substrates for CYP2B6
28. Preparation and properties of partially purified cytochrome P-450 and reduced nicotinamide adenine dinucleotide phosphate-cytochrome P450-reductase from rabbit liver microsomes
29. Characterization of baculovirus-expressed human cytochromes P450
30. Cytochrome P450TB (CYP2C): A major monooxygenase catalyzing diclofenac 4′-hydroxylation in human liver
31. Assay of mephenytoin metabolism in human liver microsomes by high-performance liquid chromatography
32. High performance liquid chromatography assays for bufuralol 1′-hydroxylase, debrisoquine 4-hydroxylase and dextromethorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver
33. Regulation of testosterone hydroxylation by rat liver microsomal cytochrome-P450
34. Comparing the predictive accuracy of models using a simple randomization test
35. The use of in vitro metabolism techniques in the planning and interpretation of drug safety studies
36. In vitro methods for assessing human hepatic drug metabolism: Their use in drug development
37. Lead development: Validation and application of high throughput screening for determination of pharmacokinetic parameters for enzyme inhibitors
38. Inhibition of coumarin 7-hydroxylase activity in human liver microsomes
39. High-throughput screening of historic collections: Observations on file size, biological targets and file diversity
40. 450 active sites
41. Autoactivation and activation of cytochrome P450s
42. CYP3A4 drug interactions: Correlation of 10 in vitro probe substrates
43. High throughput screening using fully integrated robotic screening
44. Computer-aided prediction of drug toxicity in high throughput screening
45. Predicting drug-drug interactions in silico using pharmacophores: A paradigm for the next millennium